The “top” SNP for ERICH3 was also associated with SSRI response for MDD patients enrolled in other large clinical trials (Liu et al., 2020) including the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) (Trivedi et al., 2006), the International SSRI Pharmacogenomics Consortium (ISPC) (Biernacka et al., 2016), and the Predicting Response to Depression Treatment Test (PReDICT) (Dunlop et al., 2012; Dunlop et al., 2017) trials. This evidence concerns the gene ERICH3 and major depressive disorder.